Want to join the conversation?
Under the Generics segment, sales in North America were approx. $1.1Bil in 3Q15, up 29% YoverY on a constant currency basis. $MYL's legacy business grew by 24% as a result of continued strong performance of sales from new products and higher volumes on existing products, offset by lower net pricing. $MYL launched 14 new products in the US in 3Q15.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.